tetano
Editor, Senior Moderator
Vaccine. 2016 Jan 4. pii: S0264-410X(15)01873-3. doi: 10.1016/j.vaccine.2015.12.062. [Epub ahead of print]
[h=1]A highly immunogenic vaccine against A(H7N9) influenza virus.[/h] Cao W[SUP]1[/SUP], Liepkalns J[SUP]1[/SUP], Hassan AO[SUP]2[/SUP], Kamal R[SUP]3[/SUP], Hofstetter AR[SUP]4[/SUP], Amoah S[SUP]3[/SUP], Kim JH[SUP]1[/SUP], Reber A[SUP]1[/SUP], Stevens J[SUP]5[/SUP], Katz JM[SUP]1[/SUP], Gangappa S[SUP]1[/SUP], York I[SUP]1[/SUP], Mittal SK[SUP]6[/SUP], Sambhara S[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Since the first case of human infection in March 2013, continued reports of H7N9 cases highlight a potential pandemic threat. Highly immunogenic vaccines to this virus are urgently needed to protect vulnerable populations who lack protective immunity. In this study, an egg- and adjuvant-independent adenoviral vector-based, hemagglutinin H7 subtype influenza vaccine (HAd-H7HA) demonstrated enhanced cell-mediated immunity as well as serum antibody responses in a mouse model. Most importantly, this vaccine provided complete protection against homologous A/(H7N9) viral challenge suggesting its potential utility as a pandemic vaccine.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] A/(H7N9) influenza vaccine; Adenoviral vector vaccine; Antibody responses; H7HA, cell-mediated immunity; Mouse model; Protective immunity
PMID: 26765287 [PubMed - as supplied by publisher]
[h=1]A highly immunogenic vaccine against A(H7N9) influenza virus.[/h] Cao W[SUP]1[/SUP], Liepkalns J[SUP]1[/SUP], Hassan AO[SUP]2[/SUP], Kamal R[SUP]3[/SUP], Hofstetter AR[SUP]4[/SUP], Amoah S[SUP]3[/SUP], Kim JH[SUP]1[/SUP], Reber A[SUP]1[/SUP], Stevens J[SUP]5[/SUP], Katz JM[SUP]1[/SUP], Gangappa S[SUP]1[/SUP], York I[SUP]1[/SUP], Mittal SK[SUP]6[/SUP], Sambhara S[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Since the first case of human infection in March 2013, continued reports of H7N9 cases highlight a potential pandemic threat. Highly immunogenic vaccines to this virus are urgently needed to protect vulnerable populations who lack protective immunity. In this study, an egg- and adjuvant-independent adenoviral vector-based, hemagglutinin H7 subtype influenza vaccine (HAd-H7HA) demonstrated enhanced cell-mediated immunity as well as serum antibody responses in a mouse model. Most importantly, this vaccine provided complete protection against homologous A/(H7N9) viral challenge suggesting its potential utility as a pandemic vaccine.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] A/(H7N9) influenza vaccine; Adenoviral vector vaccine; Antibody responses; H7HA, cell-mediated immunity; Mouse model; Protective immunity
PMID: 26765287 [PubMed - as supplied by publisher]